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Editorial
As we reported in the April issue of Hospital Pharmacy, a new study evaluated trends in the use of herbal and other natural products (dietary supplements). 1 The purpose of the study was to determine if the prevalence of these products has continued to increase, which products Americans use, and if the choice of individual products have changed.
A total of 8,470 subjects, 18 years of age and older, were interviewed via a telephone survey conducted from February 1998 through December 2002. During this time period, the use of dietary supplements increased from 14.2% in 1998 to 1999 to 18.8% in 2002. Although the utilization doubled for men and women 65 years of age and older there were no changes among younger subjects. Lutein use increased significantly due to its inclusion in multivitamin products but the use of Panax ginseng and Ginkgo biloba decreased. The dramatic increase in dietary supplement use we saw during the 1990s seems to have abated somewhat. Please see last month's Pulse feature for a more detailed discussion of supplements used during this study period.
An Institute of Medicine of the National Academies' report, Complementary and Alternative Medicine (CAM) in the US, was announced January 2005. 2 This extensive report calls for conventional, complementary, and alternative treatment standards to be evaluated by the same evidencebased methods. Similar research standards should be followed to evaluate both modes of treatment.
The Dietary Supplement Health and Education Act (DSHEA) requires that herbals be regulated as foods rather than drugs. Therefore,manufacturers of these agents are not required to conduct safety or efficacy testing and have no incentive to fund this research nor provide consistent methods of quality control. This Institute of Medicine (IOM) report calls on Congress and other agencies in research and industry to amend DSHEA to enforce more accurate labeling and implement quality control standards. It also recommends a regulatory format that would create incentives for privately funded research to determine the efficacy of the products.
Both the Food and Drug Administration and National Center for Complementary and Alternative Medicine have echoed the conclusions of the IOM report. A final rule on current good manufacturing practices (cGMPs) for dietary supplements is a priority of the FDA.
We see from these reports that the acceptance of herbal and dietary supplements as part of traditional medical therapy remains at high levels and, thankfully, that requirements may be forthcoming that help ensure their consistent quality, safety, and effectiveness.
